Peer Exchange
The Pharmacy Times® Peer Exchange series is built around video panel discussions featuring some of the most recognizable names in pharmaceuticals. Each program focuses on a specific disease, condition, or therapy, and boasts energetic, moderated conversation on a variety of subjects and questions pertaining to the topic at hand.
What can we help you find?
Expert oncologists and pharmacists discuss the significance of chemotherapy-free regimens in later-line settings, and the role of specialty pharmacists to direct individuals toward the appropriate treatment plan.
A discussion on when to optimally use PARP inhibitors in patients with platinum-sensitive recurrent disease and the potential for PARPi re-treatment.
Key opinion leaders consider whether frontline bevacizumab will affect second-line therapy options.
Maurie Markman, MD, leads a discussion on defining platinum-sensitive versus platinum-resistant recurrent disease, and the role of immunotherapy in managing ovarian cancer.
Annette Hood, PharmD, BCACP, discusses the role of special pharmacy programs to manage the administration of oral chemotherapy and PARP inhibitors, and emphasizes the impact medication assistance technicians have on mitigating treatment costs for patients.
Expert oncologists discuss the VELIA study and the new frontline PARP inhibitor treatment veliparib.
A discussion of the PAOLO-1 trial regimen and the rationale behind combining olaparib and bevacizumab as post-chemotherapy maintenance.
Maurie Markman, MD, leads a discussion on the design and results of the PRIMA trial, and how it has impacted practice.
Expert panelists conclude their discussion with parting advice on the management of opioid-induced constipation.
Key opinion leaders discuss the importance of HRD testing, with special consideration of tissue testing versus somatic testing.
Turning toward the future management of opioid-induced constipation, the panel defined unmet needs and potential evolutions in care.
A discussion on how to bring awareness to clinicians that are not aware of the role of an oncology pharmacist.